James Knibbs, who brings a wide breadth of experience in sales leadership, is the new vice president of UK, Ireland, and Australia at Dublin, Ireland-based Mainstay Medical Holdings.
James Knibbs: New VP of UK/Ireland/Australia at Mainstay Medical

Knibbs, who is steeped in sales leadership of the implantable device realm, was a territory sales manager at Stryker Instruments, then held several roles at Nevro. At Nevro, he was business development manager for North UK to UK Country Manager, and then served as senior area director for Western Europe.
Mainstay Medical is growing significantly and OTW asked Mainstay CEO Jason Hannon about his companies recent decision to expand staff and operations: “We continue to demonstrate the clinical value ReActiv8 brings to patients and are preparing to expand the availability of this compelling therapy in multiple countries.”
“Each of these individuals brings incredible leadership and experience to help build our commercial capabilities, expand in our existing markets, and launch in the U.S. Each of them is experienced in bringing disruptive new technologies to the market and will help us deliver ReActiv8 to patients suffering from mechanical chronic low back pain and the physicians treating this condition. Collectively they complement the existing strong leadership we already have and will leverage the deep history of clinical and scientific leadership we’ve developed.”
James Knibbs told OTW, “I am thrilled to continue to expand access to ReActiv8 for patients in Australia, the UK and Ireland. Launching a novel therapy is a rare opportunity, which affords us the ability to focus on building stellar teams and partnering with physicians to select and care for the right patients.”
“James is a demonstrated market builder. He has the unique opportunity to work with our physician partners in the UK and Australia who are the most experienced ReActiv8 implanters in the world,” stated Jason Hannon to OTW.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.